Carcinoembryonic Antigen Market Size To Reach Around US$ 3.45 Billion By 2033, Driven By Growing Cancer Burden And Personalized Medicine S&S Insider

(MENAFN- GlobeNewsWire - Nasdaq) U.S. Carcinoembryonic Antigen (CEA) Market to Surpass US$ 1.3 Billion By 2033, Supported by High Cancer Incidence and Advanced Diagnostics

Austin, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Carcinoembryonic Antigen Market Size Analysis:

According to S&S Insider Research, the Carcinoembryonic Antigen Market was valued at USD 2.17 billion in 2025E and is projected to reach USD 3.45 billion by 2033, growing at a CAGR of 5.99% during 2026–2033.

In the United States, the Carcinoembryonic Antigen market accounted for USD 824.78 million in 2025E and is forecast to expand to USD 1.30 billion by 2033, reflecting a CAGR of 5.91% from 2026–2033.

Get Sample Report of Carcinoembryonic Antigen Market @

Market Growth Overview

The global Carcinoembryonic Antigen market is expanding rapidly due to the rising prevalence of cancers including colorectal, gastric, pancreatic, breast, and lung cancer. CEA tests are widely used for early detection, therapeutic monitoring, and recurrence tracking, making them a valuable biomarker in oncology.

Increased awareness among physicians and patients about the role of tumor markers, together with government and private cancer screening programs, is accelerating adoption. In September 2024, the European Cancer Organization reported that more than 60% of eligible adults participated in biomarker-based cancer screening, further boosting demand for CEA testing.

Technological advances such as high-sensitivity immunoassays and automated platforms are enabling earlier, faster, and more accurate testing, while integration into personalized medicine programs ensures tailored treatment monitoring. Together, these drivers create a favorable growth outlook for the CEA market globally.

Major Players Analysis Listed in the Carcinoembryonic Antigen Market Report are:

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• bioMérieux SA
• Thermo Fisher Scientific
• Beckman Coulter
• Sysmex Corporation
• Hologic, Inc.
• Ortho Clinical Diagnostics
• Bio-Rad Laboratories
• Diasorin S.p.A.
• Epitope Diagnostics
• Immuno-Biological Laboratories
• Inova Diagnostics
• Euro Diagnostica AB
• Other Players

Carcinoembryonic Antigen Market Segmentation Dynamics

By Antigen: With a 60.87% share in 2025E, the molecular test segment had the largest share, due to their high accuracy, high sensitivity, and effectiveness in early cancer detection. One of the major contributors to the increasing market growth for this segment includes the rising demand for accuracy in diagnosing diseases along with the need for advanced technologies in laboratories. Ongoing developments in the field of rapid assays are expected to augment growth of serology test platforms segment at a fastest growth rate of 6.24%, during the forecast period, from 2026–2033, on account of rising demand for minimally invasive, cost-effective testing worldwide.

By Type: Breast cancer segment was the largest segment and accounted for a share of 18.98% in 2025E as it is one of the most commonly diagnosed cancers worldwide and CEA plays an important role in the early detection and monitoring of treatment. The rising awareness of patients and doctors towards the importance of biomarker-driven care also plays role in this. Colorectal cancer segment is expected to be the fastest-growing during 2026–2033, with a CAGR of 7.19%, driven primarily by increasing incidence and guidelines broadening the role of CEA in recurrence surveillance.

By Gender: In terms of sample coverage, the vast majority of the breast and ovarian cancer screening programs/manifestations is responsible for the dominant market share of 64.89% for female segment in 2025E. Growing awareness among women about monitoring biomarkers adds to increased uptake. On the other hand, the male segment is anticipated to register the highest growth rate, with a CAGR of 6.24% during the forecasted period of 2026–2033, owing to the rising incidence of colorectal, pancreatic and lung cancers among men, along with growing acceptance of biomarker testing among men.

By End User: Hospitals capture the highest market share at 49.85% in 2025E, due to better advanced diagnostic infrastructure, huge patient influx, and provision of end-to-end oncology services. Hospital-based CEA surveillance is included in an overall integrated cancer care strategy. The laboratories segment, on the other hand, is expected to be the fastest growing segment during 2026–2033 with a CAGR of 6.60% driven by increasing outsourcing of testing, expansion of private diagnostic chains, and rising demand for personalized monitoring solutions.

Need Any Customization Research on Carcinoembryonic Antigen Market, Enquire Now:

Carcinoembryonic Antigen Market Key Segmentation:

By Type

• Colorectal Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Breast Cancer
• Thyroid Cancer
• Others

By Gender

• Male
• Female

By Antigen

• Molecular Test
• Serology Test

By End User

• Hospitals
• Laboratories
• Others

Regional Analysis

Dominating the global Carcinoembryonic Antigen market in 2025, North America held a commanding share of over 44%. Several factors contributed to this leadership. First, the high prevalence of cancer in the region fuels strong demand for CEA tests. In the United States, colorectal and breast cancer cases continue to rise, creating significant market need. Second, advanced healthcare systems and robust diagnostic infrastructure support broad adoption of biomarker assays. Finally, favorable reimbursement structures make CEA testing more accessible to patients. These factors combine to position North America as the leader in CEA testing adoption.

Europe is projected to be the second-largest regional market. Countries such as Germany, the UK, and France are characterized by robust cancer screening programs and high awareness among patients and providers. National programs to support early detection, combined with the presence of leading diagnostic players, continue to drive market growth. Furthermore, ongoing advancements in immunoassay technology and government-backed research into cancer biomarkers are reinforcing Europe's position.

The Asia Pacific region is forecast to grow at the fastest pace, with a projected CAGR of 6.88%. Expanding healthcare infrastructure, government-sponsored awareness programs, and the growing middle class in China and India are fueling demand. Japan, with its aging population and advanced cancer care facilities, represents another key revenue contributor. Rising cancer incidence in India, particularly in colorectal and gastric cancers, is further driving the expansion of the CEA testing market in the region.

In Latin America and the Middle East & Africa, market development is accelerating. Brazil, South Africa, and GCC countries are increasing investments in cancer care, expanding hospital and diagnostic facilities, and raising awareness about early cancer detection. These factors make LATAM and MEA emerging regions with high long-term potential for Carcinoembryonic Antigen testing adoption.

Exclusive Sections of the Report (The USPs):

• PROCEDURE & TESTING METRICS – helps you analyze annual test volumes, turnaround times, and accuracy benchmarks (sensitivity & specificity) across hospitals, labs, and cancer centers.
• MARKET ADOPTION & PENETRATION INDEX – helps you track adoption levels of CEA testing across healthcare providers, reimbursement coverage trends, and penetration rates by end-user segments.
• PRODUCT PERFORMANCE SCORECARD – helps you assess usage patterns of immunoassay kits, ELISA kits, and automated analyzers, alongside comparative accuracy between conventional and advanced testing systems.
• SUPPLY CHAIN & DISTRIBUTION DYNAMICS – helps you understand distribution channel shares, inventory turnover ratios, and global trade flows of CEA assay kits.
• COMPETITIVE LANDSCAPE – helps you evaluate the positioning of leading diagnostic players based on product portfolios, regional market reach, and technological advancements in CEA testing.

Get the Full Report of Carcinoembryonic Antigen Market Report (Single-User License):

About Us:

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

MENAFN19092025004107003653ID1110084669